Science, pharmacoeconomics and ethics in drug R&D: A sustainable future scenario?

Nature Reviews Drug Discovery

Volumn 3, Issue 6, 2004, Pages 521-526

  Preziosi, Paolo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ASTEMIZOLE; BENOXAPROFEN; BROMFENAC; CATECHIN; CERIVASTATIN; CISAPRIDE; DEXFENFLURAMINE; ENCAINIDE; FENFLURAMINE; FLOSEQUINAN; GEMFIBROZIL; GREPAFLOXACIN; INDOPROFEN; ISOXICAM; LEVACETYLMETHADOL; MIBEFRADIL; NEW DRUG; NOMIFENSINE; PHENYLPROPANOLAMINE; RAPACURONIUM BROMIDE; SULOCTIDIL; SUPROFEN; TEMAFLOXACIN; TERFENADINE; TIENILIC ACID; TROGLITAZONE; UNINDEXED DRUG; ZIMELDINE; ZOMEPIRAC;

ANAPHYLAXIS; AORTA VALVE REGURGITATION; ARTICLE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DESIGN; DRUG FATALITY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; DRUG WITHDRAWAL; EPIDERMOLYSIS; FLANK PAIN; FOOD AND DRUG ADMINISTRATION; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEMOLYTIC ANEMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; ISCHEMIC COLITIS; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; MEDICAL ETHICS; MITRAL VALVE REGURGITATION; NEUROLOGIC DISEASE; NONHUMAN; OBSTRUCTIVE JAUNDICE; PHARMACOECONOMICS; PRIORITY JOURNAL; QT PROLONGATION; RHABDOMYOLYSIS; SUSTAINABLE DEVELOPMENT; TORSADE DES POINTES; UNITED STATES;

EID: 3042643738     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1418     Document Type: Article

References (47)

1. Geiling, E. M. K. & Cannon, P. R. Pathologic effects of elixir of sulphanilamide (diethylene glycol) poisoning. J. Am. Med. Assoc. 111, 919-926 (1938).
2. Temple, R. in Principles of Pharmacology (ed. Munson, P. L.) 1643-1663 (Chapman A. Hall, New York, 1995).
3. Federal Food, Drug and Cosmetic Act. As amended. Code of Federal Regulations, Title 21, Publication n. 667340 (US Government Printing Office, Washington DC, 1963).
4. Tishler, M. The role of industry in national science policy. The people's welfare: health and medicine. Persp. Biol. Med. 13, 528-535 (1970).
5. Berkowitz, B. A. & Katzung, B. G. Basic and Clinical Pharmacology 9th edn (ed. Katzung, B. G.) 67-74 (Lange Medical/McGraw-Hill, New York, 2004).
6. Pritchard, J. F. et al. Making better drugs: decision gates in non-clinical drug development. Nature Rev. Drug Discov. 2, 542-553 (2003)
7. DiMasi, J. A., Hansen, R. W., Grabowski, H. G. & Lasagna, L. Research and development costs for new drugs by therapeutic category: a study of the U. S. pharmaceutical industry. PharmacoEconomics 7, 152-169 (1995).
8. DiMasi, J. A. Success rates for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther. 58, 1-14 (1995).
9. Monzo, A. & Mehta, D. Are single-dose toxicology studies in animals adequate to support single doses of a new drug in humans? Clin. Pharmacol. Ther. 59, 258-264 (1996).
10. Polastro, E. T. Managing primary development for competitive edge. Scrip Magazine, 33-34 (November 1995).
11. Editorial. 18 new blockbusters by 2008, with $ 24 billion sales forecast. PharmacoMarket Letter 29, 24-25 (July 1, 2002).
12. DiMasi, J. A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. 69, 297-307 (2001).
13. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
14. Styliani, E. R. & D costs are staggering. Pharmaco-business 48 (January/February 2002).
15. Greaves, P., Williams, A. & Eve, M. First dose of potential new medicines to humans: how animals help. Nature Rev. Drug Discov. 3, 226-236 (2004).
16. Claude, J. R. Les études de sécurité des produits en dévelopment dans l'industrie pharmaceutique. Ann. Pharm. Fr. 59, 324-330 (2001).
17. Regan, T. Defending Animal Rights (University of Illinois Press, 2001).
18. Roberts, I., Kwan, I., Evans, P. & Haig, S. Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ 324, 474-476 (2002).
19. Paton, W. Man and mouse - animals in medical research 44 (Oxford Med. Press, 1984).
20. Ellen Frankel, P. & Jeffrey, P. Why Animal Experimentation Matters: the Use of Animals in Medical Research (Transactions Publishers, 2001).
21. Shaw, W. H. Cost and benefits of inflicting pain. Nature 414, 396-397 (2001).
22. Wickelgren, I. Animal studies raise hopes for spinal cord repair. Science 297, 178-181 (2002).
23. Nies, A. S. in Goodman and Gilman's The Pharmacological Basis of Therapeutics 10th edn (eds. Hardman, J. G. & Limbird, L. E) 45-66 (McGraw Hill, New York, 2001).
24. Reichert, J. M. Trends in development and approval for the new therapeutics in the United States. Nature Rev. Drug Discov. 2, 695-702 (2003).
25. DiMasi, J. New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 69, 286-296 (2001).
26. Mitka, M. Accelerated approval scrutinized. Confirmatory Phase 4 studies or new drug languish. J. Am. Med. Assoc. 289, 3227-3229 (2003).
27. Goldstein, A., Aronow, L. & Kalman, S. M. Principles of Drug Action. The Basis of Pharmacology 2nd edn 815 (J. Wiley a. Sons, Chichester, 1974).
28. Lewis, I. A. Post marketing surveillance. how many patients? Trends Pharmacol. Sci. 2, 93-94 (1971).
29. Freeman, J. in Drug Safety: A Shared Responsibility, International Drug Surveillance Department Glaxo Group Res. Ltd. 13-26 (Churchill Livingstone, Edinburgh 1991).
30. Generali, J. A. Drug withdrawals in the US: 1980 to 2001. Drug facts and comparison news 43-45 (Facts and Comparisons, a Wolters Kluwer Company, St. Louis, 2001).
31. McQuaid, K. R. in Basic and Clinical Pharmacology (ed. Katzung, B. G.) 1049 (Lange Medical/McGraw Hill, New York, 2004).
32. Farmer, J. A. Learning from the cerivastatin experience. Lancet 358, 1383-1384 (2001).
33. Katzung, B. G. in Basic and Clinical Pharmacology 9th edn (ed. Katzung, B. G.) 267 (Lange Medical/McGraw Hill, New York, 2004).
34. Elliott, W. I. Nefazodone under attack once again. Pharmacol. Watch, May 2003, 2 (Thomson American Health Consultants, Atlanta 2003).
35. Edwards, I. R. Withdrawing drugs: nefazodone, the start of the latest saga. Lancet 361, 1240 (2003).
36. Editorial. R. & D. revolution remains just around the corner. Scrip Magazine February, 72-73 (2002).
37. Watters, J. W. & McLeod, H. L. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol. Sci. 24, 55-58 (2003).
38. Evans, W. E. & Mcleod, H. L. Pharmacogenomics - drug disposition, drug target, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
39. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
40. Weinstein, J. N. Pharmacogenomics - teaching old drugs new tricks. N. Engl. J. Med. 9, 1408-1409 (2000).
41. Roses, A. D. Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541-549 (2002).
42. 2002 Workshop on Pharmacogenetics/Pharmacogenomics in drug development and regulatory decision-making. Chairpersons: L. Lesko, R. A Salerno. www.fda.gov/CDER/Calendar/MEETING/PHARMA52002/default.htm
43. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions. J. Am. Med. Assoc. 286, 2270-2279 (2001).
44. Holmes, E. Methodological approach in metabonomics. Tox. Lett. 144 (Suppl. 1), S4 (2003).
45. Thompson, D. C. Methodological approaches in proteomics. Tox. Lett. 144 (Suppl. 1), S4 (2003).
46. Editorial. Genomics may increase costs of NCE development says Lehman Bros. PharmaMarkeletter 28, 24-25, February 2001.
47. Lord, P. G. Progress in applying genomics in drug development. Tox. Lett. 144 (Suppl. 1), S4 (2003).